OBJECTIVE: The primary objective was to comprehensively assess the association between single nucleotide polymorphisms (rs562556 and rs2479409) in the PCSK9 gene with biochemical parameters - C-reactive protein (CRP), glucose (GLU), triglyceride (TAG), low-density lipoprotein cholesterol (LDL CHOL), non-high-density lipoprotein cholesterol (non HDL CHOL), high-density lipoprotein cholesterol (HDL CHOL), cholesterol (CHOL), and anthropometric parameters (visceral fat), overweight/obesity and cardiovascular risk. METHODS: A total of 71 women aged 23-64 years were divided into three groups based on body mass index (BMI). BMI ≥ 25/≥ 30 kg/m2 was the criterion for assessment of overweight/obesity. Anthropometric, biochemical and genetic examinations were performed on the probands. Changes in markers in each group and their association with cardiovascular risk were monitored. RESULTS: We can conclude that in our study population we observed differences between the BMI categories for biochemical markers (CRP, LDL CHOL, non HDL CHOL, HDL CHOL, LDL CHOL) and anthropometric marker (visceral fat). Atherogenic index of plasma (AIP), Castelli's Risk Index I (CRI-I) and atherogenic coefficient (AC) confirmed high cardiovascular risk for the obese women category (0.045); (< 0.013); (< 0.010). Genotype and allele frequencies for the PCSK9 gene in the overweight and obese groups showed higher allele frequencies of allele A for both polymorphisms of the gene. CONCLUSIONS: PCSK9 gene expression is associated with biological processes such as lipid metabolism and inflammation. Cholesterol-lowering therapies are the gold standard for reducing the risk of cardiovascular mortality and morbidity. Administration of monoclonal antibodies (mAbs) against PCSK9 is a novel lipid-lowering therapeutic approach in adults to reduce the risk of cardiovascular disease.

Department of Biology Faculty of Humanities and Natural Sciences University of Presov Presov Slovak Republic

Department of Public Health and Hygiene Faculty of Medicine Pavol Jozef Safarik University Kosice Slovak Republic

Department of Technical Disciplines in Health Care Faculty of Health Care University of Presov Presov Slovak Republic

See more in PubMed

Battineni G, Sagaro GG, Chintalapudi N, Amenta F, Tomassoni D, Tayebati SK. Impact of obesity-induced inflammation on Cardiovascular Diseases (CVD). Int J Mol Sci. 2021 Apr 30;22(9):4798. doi: 10.3390/ijms22094798. PubMed DOI

World Health Organization. Cardiovasculare diseases [Internet]. Geneva: WHO; 2023 [cited 2023 Dec 13]. Available from: https://www.who.int/europe/health-topics/cardiovascular-diseases#tab=tab_1.

Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014 Mar 14;114(6):1022-36. PubMed DOI

Vlachopoulos C, Terentes-Printzios D, Georgiopoulos G, Skoumas I, Koutagiar I, Ioakeimidis N, et al. Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: a systematic review and meta-analysis. Atherosclerosis. 2016 Sep;252:50-60. PubMed DOI

Bordicchia M, Spannella F, Ferretti G, Bacchetti T, Vignini A, Di Pentima C, et al. PCSK9 is expressed in human visceral adipose tissue and regulated by insulin and cardiac natriuretic peptides. Int J Mol Sci. 2019 Jan 9;20(2):245. doi: 10.3390/ijms20020245. PubMed DOI

Nozue T. Lipid lowering therapy and circulating PCSK9 concentration. J Atheroscler Thromb. 2017 Sep 1;24(9):895-907. PubMed DOI

Khedoe PP, Hoeke G, Kooijman S, Dijk W, Buijs JT, Kersten S, et al. Brown adipose tissue takes up plasma triglycerides mostly after lipolysis. J Lipid Res. 2015 Jan;56(1):51-9. PubMed DOI

Olamoyegun MA, Oluyombo R, Asaolu SO. Evaluation of dyslipidemia, lipid ratios, and atherogenic index as cardiovascular risk factors among semi-urban dwellers in Nigeria. Ann Afr Med. 2016 Oct-Dec;15(4):194-9. PubMed DOI

Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G, et al. Atherogenic Index of Plasma (AIP): a marker of cardiovascular disease. Med J Islam Repub Iran. 2015 Jul 25;29:240.

Ragusa R, Basta G, Neglia D, De Caterina R, Del Turco S, Caselli C. PCSK9 and atherosclerosis: looking beyond LDL regulation. Eur J Clin Invest. 2021 Apr;51(4):e13459. doi: 10.1111/eci.13459. PubMed DOI

Luquero A, Badimon L, Borrell-Pages M. PCSK9 functions in atherosclerosis are not limited to plasmatic LDL-cholesterol regulation. Front Cardiovasc Med. 2021 Mar 23;8:639727. doi: 10.3389/fcvm.2021.639727. PubMed DOI

Artunc F. Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome? Kidney Int. 2020 Dec;98(6):1393-5. PubMed DOI

Bernelot Moens SJ, Neele AE, Kroon J, van der Valk FM, Van den Bossche J, Hoeksema MA, et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. Eur Heart J. 2017 May 21;38(20):1584-93. PubMed DOI

Adorni MP, Cipollari E, Favari E, Zanotti I, Zimetti F, Corsini A, et al. Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis. 2017 Jan;256:1-6. PubMed DOI

Guo Y, Yan B, Gui Y, Tang Z, Tai S, Zhou S, et al. Physiology and role of PCSK9 in vascular disease: potential impact of localized PCSK9 in vascular wall. J Cell Physiol. 2021 Apr;236(4):2333-51. PubMed DOI

Barale C, Melchionda E, Morotti A, Russo I. PCSK9 biology and its role in atherothrombosis. Int J Mol Sci. 2021 May 30;22(11):5880. doi: 10.3390/ijms22115880. PubMed DOI

Cao YX, Jin JL, Sun D, Liu HH, Guo YL, Wu NQ, et al. Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy. J Transl Med. 2019 Nov 11;17(1):367. doi: 10.1186/s12967-019-2123-9. PubMed DOI

Andreadou I, Tsoumani M, Vilahur G, Ikonomidis I, Badimon L, Varga ZV, et al. PCSK9 in myocardial infarction and cardioprotection: importance of lipid metabolism and inflammation. Front Physiol. 2020 Nov 12;11:602497. doi: 10.3389/fphys.2020.602497. PubMed DOI

Seidah NG. The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer. J Lipid Res. 2021;62:100130. doi: 10.1016/j.jlr.2021.100130. PubMed DOI

Zhang Z, Wei TF, Zhao B, Yin Z, Shi QX, Liu PL, et al. Sex differences associated with circulating PCSK9 in patients presenting with acute myocardial infarction. Sci Rep. 2019 Feb 28;9(1):3113. doi: 10.1038/s41598-018-35773-x. PubMed DOI

Cui Q, Ju X, Yang T, Zhang M, Tang W, Chen Q, et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis. 2010 Dec;213(2):632-6. PubMed DOI

Khedoe PP, Hoeke G, Kooijman S, Dijk W, Buijs JT, Kersten S, et al. Brown adipose tissue takes up plasma triglycerides mostly after lipolysis. J Lipid Res. 2015 Jan;56(1):51-9. PubMed DOI

Ma CY, Shi XY, Wu YR, Zhang Y, Yao YH, Qu HL, et al. Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway. Ann Transl Med. 2021 Oct;9(20):1517. doi: 10.21037/atm-20-8106. PubMed DOI

Gago-Dominguez M, Sobrino T, Torres-Español M, Calaza M, Rodríguez-Castro E, Campos F, et al. Obesity-related genetic determinants of stroke. Brain Commun. 2021 Apr 19;3(2):fcab069. doi: 10.1093/braincomms/fcab069. PubMed DOI

Zamarrón-Licona E, Rodríguez-Pérez JM, Posadas-Sánchez R, Vargas-Alarcón G, Baños-González MA, Borgonio-Cuadra VM, et al. Variants of PCSK9 gene are associated with subclinical atherosclerosis and cardiometabolic parameters in Mexicans. The GEA project. Diagnostics (Basel). 2021 Apr 26;11(5):774. doi: 10.3390/diagnostics11050774. PubMed DOI

Gai MT, Adi D, Chen XC, Liu F, Xie X, Yang YN, et al. Polymorphisms of rs2483205 and rs562556 in the PCSK9 gene are associated with coronary artery disease and cardiovascular risk factors. Sci Rep. 2021;11(1):11450. doi: 10.1038/s41598-021-90975-0. PubMed DOI

Chuan J, Qian Z, Zhang Y, Tong R, Peng M. The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis. Lipids Health Dis. 2019 Apr 30;18(1):105. doi: 10.1186/s12944-019-1036-1. PubMed DOI

Uzunget SB, Sahin KE. Atherogenic index of plasma is an independent predictor of mitral annular calcification. BMC Cardiovasc Disord. 2022 Nov 30;22(1):511. doi: 10.1186/s12872-022-02891-4. PubMed DOI